July 26 (Reuters) - U.S. regulators have asked Pfizer Inc
-BioNTech and Moderna Inc to expand
the size of ongoing trials testing their COVID-19 vaccines in
children aged between five and 11, the New York Times reported
The Food and Drug Administration has indicated that the
current strength of the studies was inadequate to detect the
rare side effects, including myocarditis, an inflammation of the
heart muscle, and pericarditis, an inflammation of the lining
around the heart, the report said. (https://nyti.ms/3xgzuWZ)
The health regulator has asked the companies to include
3,000 children in their trials, almost double the original
number of study participants, the report said, citing people
familiar with the matter.
FDA, Pfizer and Moderna did not immediately respond to
Reuters request for comment.
(Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini